PE20211757A1 - Formas cristalinas y formas de sal de un inhibidor de cinasa - Google Patents

Formas cristalinas y formas de sal de un inhibidor de cinasa

Info

Publication number
PE20211757A1
PE20211757A1 PE2021000862A PE2021000862A PE20211757A1 PE 20211757 A1 PE20211757 A1 PE 20211757A1 PE 2021000862 A PE2021000862 A PE 2021000862A PE 2021000862 A PE2021000862 A PE 2021000862A PE 20211757 A1 PE20211757 A1 PE 20211757A1
Authority
PE
Peru
Prior art keywords
forms
relates
compound
crystalline forms
kinase inhibitor
Prior art date
Application number
PE2021000862A
Other languages
English (en)
Inventor
Stephan D Parent
Frenel Demorin
Khalid Shah
Sagar Shakya
Peter Wong
Courtney S Johnson
Melanie Janelle Bevill
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20211757A1 publication Critical patent/PE20211757A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a formas cristalinas de la base libre del inhibidor de c-Met: N-(4-fluorofenil)-N-(4-((7-metoxi-6- (metilcarbamoil)quinolin-4-il)oxi)fenil)ciclopropano-1,1- dicarboxamida, (Compuesto 1). La invencion tambien se refiere a formas cristalinas de sales del Compuesto 1. La invencion tambien se refiere a composiciones farmaceuticas que comprenden los polimorfos solidos de la base libre y sales del Compuesto 1. La invencion se refiere ademas a metodos para tratar una enfermedad, trastorno o sindrome mediado al menos en parte por la modulacion de la actividad in vivo de una proteina cinasa.
PE2021000862A 2018-12-13 2019-12-12 Formas cristalinas y formas de sal de un inhibidor de cinasa PE20211757A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US201962856469P 2019-06-03 2019-06-03
PCT/US2019/065972 WO2020123800A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor

Publications (1)

Publication Number Publication Date
PE20211757A1 true PE20211757A1 (es) 2021-09-07

Family

ID=69160358

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000862A PE20211757A1 (es) 2018-12-13 2019-12-12 Formas cristalinas y formas de sal de un inhibidor de cinasa

Country Status (20)

Country Link
US (1) US20230029213A1 (es)
EP (1) EP3894012A1 (es)
JP (2) JP2022512399A (es)
KR (1) KR20210102381A (es)
CN (1) CN113329790A (es)
AU (1) AU2019395419A1 (es)
BR (1) BR112021011333A2 (es)
CA (1) CA3122840A1 (es)
CL (1) CL2021001537A1 (es)
CO (1) CO2021007613A2 (es)
CR (1) CR20210375A (es)
GE (1) GEP20247596B (es)
IL (1) IL283860A (es)
MA (1) MA54458A (es)
MX (1) MX2021006951A (es)
PE (1) PE20211757A1 (es)
PH (1) PH12021551356A1 (es)
SG (1) SG11202105949RA (es)
TW (1) TW202039440A (es)
WO (1) WO2020123800A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117603138A (zh) * 2018-01-26 2024-02-27 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
CR20220551A (es) * 2020-04-30 2022-12-07 Exelixis Inc Procesos para la preparación de un inhibidor de cinasa
MX2023001298A (es) 2020-07-31 2023-02-22 Exelixis Inc Combinaciones para el tratamiento de cancer.
CA3196001A1 (en) 2020-11-05 2022-05-12 Exelixis, Inc. Pharmaceutical compositions of a kinase inhibitor
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
TW202340148A (zh) 2021-12-22 2023-10-16 美商艾克塞里克斯公司 激酶抑制劑之結晶形式及鹽形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2925655T3 (es) * 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
JP5039027B2 (ja) 2005-04-15 2012-10-03 ネオジェニックス オンコロジー， インコーポレイテッド 結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原
KR101947702B1 (ko) 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
DK2992017T3 (da) 2013-05-02 2021-01-25 Anaptysbio Inc Antistoffer rettet mod programmeret død-1 (pd-1)
CN117603138A (zh) * 2018-01-26 2024-02-27 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
SG11202111978VA (en) * 2019-06-03 2021-11-29 Exelixis Inc Crystalline salt forms of a kinase inhibitor

Also Published As

Publication number Publication date
CA3122840A1 (en) 2020-06-18
TW202039440A (zh) 2020-11-01
WO2020123800A1 (en) 2020-06-18
IL283860A (en) 2021-07-29
AU2019395419A1 (en) 2021-07-01
PH12021551356A1 (en) 2021-12-06
US20230029213A1 (en) 2023-01-26
BR112021011333A2 (pt) 2021-08-31
JP2022512399A (ja) 2022-02-03
MX2021006951A (es) 2021-07-15
SG11202105949RA (en) 2021-07-29
CL2021001537A1 (es) 2022-02-04
MA54458A (fr) 2021-10-20
EP3894012A1 (en) 2021-10-20
CN113329790A (zh) 2021-08-31
GEP20247596B (en) 2024-02-26
KR20210102381A (ko) 2021-08-19
JP2024038167A (ja) 2024-03-19
CR20210375A (es) 2021-08-18
CO2021007613A2 (es) 2021-06-21

Similar Documents

Publication Publication Date Title
PE20211757A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
CO2022016323A2 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica que constituye el mismo
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
CY1123801T1 (el) Παραγωγα αρωματικου σουλφοναμιδιου
CY1124652T1 (el) Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CO2021000456A2 (es) Compuestos antagonistas de pcsk9 referencia recíproca a solicitudes relacionadas
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
CU20170026A7 (es) Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf
CL2020003101A1 (es) Sales de sepiapterina farmacéuticamente aceptables.
CL2021003205A1 (es) Formas de sales cristalinas de un inhibidor de cinasas
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
UY30460A1 (es) Compuestos terapéuticos
UY32535A (es) Métodos e intermediarios para la preparación de agentes farmacéuticos
UY30244A1 (es) Un proceso para preparar derivados de tetrahidroquinolina
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
AR102457A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
MX2021015853A (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida.
PE20240223A1 (es) Composiciones farmaceuticas de un inhibidor de cinasa
EA202191620A1 (ru) Твердые формы, содержащие (s)-4-(4-(4-(((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-4-ил)окси)метил)бензил)пиперазин-1-ил)-3-фторбензонитрил и его соли, и содержащие их композиции и способы их применения
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
AR051473A1 (es) Derivados de dicarboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades asociadas al factor de coagulacion xa.
BR112022014278A2 (pt) Conjugados de composto proteico-antiviral
BR112022024700A2 (pt) Inibidores de atr e usos dos mesmos